Walgreens Boots Alliance should be a private company before the end of the year after jumping the potential hurdle of a ...

Walgreens Boots Alliance shareholders gave the thumbs-up to the company's private-equity buyout by Sycamore Partners, with ...

Walgreens Boots Alliance (WBA) said on Friday that the struggling drug retailer’s shareholders approved its $10 billion ...

Shareholders for Walgreens Boots Alliance overwhelmingly voted to approve the company’s sale to Sycamore Partners, with 96% of shareholders at a special meeting voting to green-light the merger, ...

The deal, announced on March 6, would allow Sycamore Partners to take Walgreens private. The drug-store chain expects the transaction to close in the third or fourth quarter of 2025.

US pharmacy Walgreens Boots Alliance (WBA) shareholders have given approval to the company's acquisition by Sycamore Partners Management affiliated entities. The preliminary results revealed that 96% ...

The partnership enriches Veeva Data Cloud products and allows Walgreens to better serve life sciences through access to Veeva Data Cloud and Veeva Clinical Platform.

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Chief Clinical Trials Officer Ramita Tandon said the clinical trials unit has "a tremendous amount of commitment" from Walgreens' leadership.

Walgreens Boots Alliance (WBA) shareholders have voted in favor of the company’s acquisition by Sycamore Partners, with ...

Walgreens Boots’ WBA various strategic partnerships are expected to benefit the company over the long run. However, the prevailing tough macroeconomic environment might hamper the company’s ...

Shareholders of Boots ’ parent company, Walgreens Boots Alliance (WBA), have approved the company’s previously-announced ...